Hyperlipidemia Therapeutics
1. Crestor patent expiration
Treatment: Use of rosuvastatin calcium to reduce elevated total-c, ldl-c, apob, nonhdl-c or tg levels; To increase hdl-c in adult patients with primary hyperl...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6858618 | ASTRAZENECA | Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia |
Dec, 2021
(4 years ago) | |
|
US6316460 (Pediatric) | ASTRAZENECA | Pharmaceutical compositions |
Feb, 2021
(4 years ago) | |
| US7030152 | ASTRAZENECA | Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
Apr, 2018
(7 years ago) | |
| US7964614 | ASTRAZENECA | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
Apr, 2018
(7 years ago) | |
|
USRE37314 (Pediatric) | ASTRAZENECA | Pyrimidine derivatives |
Jul, 2016
(9 years ago) | |
| US6316460 | ASTRAZENECA | Pharmaceutical compositions |
Aug, 2020
(5 years ago) | |
|
US7030152 (Pediatric) | ASTRAZENECA | Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
Oct, 2018
(7 years ago) | |
|
US7964614 (Pediatric) | ASTRAZENECA | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
Oct, 2018
(7 years ago) | |
|
US6858618 (Pediatric) | ASTRAZENECA | Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia |
Jun, 2022
(3 years ago) | |
| USRE37314 | ASTRAZENECA | Pyrimidine derivatives |
Jan, 2016
(10 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-573) | Nov 06, 2011 |
| New Indication(I-611) | Oct 16, 2012 |
| New Indication(I-621) | Feb 08, 2013 |
| Pediatric Exclusivity(PED) | Apr 16, 2013 |
| New Patient Population(NPP) | Nov 20, 2018 |
| New Indication(I-732) | May 27, 2019 |
| Orphan Drug Exclusivity(ODE) | May 27, 2023 |
| Orphan Drug Exclusivity(ODE-118) | May 27, 2023 |
Drugs and Companies using ROSUVASTATIN CALCIUM ingredient
Market Authorisation Date: 12 August, 2003
Dosage: TABLET
How can I launch a generic of CRESTOR before it's drug patent expiration?
More Information on Dosage
CRESTOR family patents
2. Livalo patent expiration
Treatment: Adjunctive therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein b, triglycerides and to increase hdl-c in adult patients with primary
LIVALO IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5753675 | KOWA CO | Quinoline analogs of mevalonolactone and derivatives thereof |
May, 2015
(10 years ago) | |
| US6465477 | KOWA CO | Stable pharmaceutical composition |
Dec, 2016
(9 years ago) | |
|
US5856336 (Pediatric) | KOWA CO | Quinoline type mevalonolactones |
Jun, 2021
(4 years ago) | |
| US5856336 | KOWA CO | Quinoline type mevalonolactones |
Jan, 2021
(5 years ago) | |
| US5854259 | KOWA CO | Quinoline type mevalonolactones |
Dec, 2015
(10 years ago) | |
| US7022713 | KOWA CO | Hyperlipemia therapeutic agent |
Feb, 2024
(1 year, 10 months ago) | |
| US8557993 | KOWA CO | Crystalline forms of pitavastatin calcium |
Feb, 2024
(1 year, 11 months ago) | |
|
US7022713 (Pediatric) | KOWA CO | Hyperlipemia therapeutic agent |
Aug, 2024
(1 year, 4 months ago) | |
|
US8557993 (Pediatric) | KOWA CO | Crystalline forms of pitavastatin calcium |
Aug, 2024
(1 year, 5 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 03, 2014 |
| New Patient Population(NPP) | May 16, 2022 |
| Pediatric Exclusivity(PED) | Nov 16, 2022 |
Drugs and Companies using PITAVASTATIN CALCIUM ingredient
NCE-1 date: 16 November, 2021
Market Authorisation Date: 03 August, 2009
Dosage: TABLET
How can I launch a generic of LIVALO before it's drug patent expiration?
More Information on Dosage
LIVALO family patents
3. Welchol patent
expiration
Treatment: Use as a bile acid sequestrant for lowering cholesterol; A method for reducing serum glucose levels in adults with type 2 diabetes mellitus; Use as a bile acid sequestrant
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5693675 | COSETTE | Alkylated amine polymers |
Dec, 2014
(11 years ago) | |
| US6784254 | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Apr, 2014
(11 years ago) | |
| US6433026 | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Apr, 2014
(11 years ago) | |
| US5607669 | COSETTE | Amine polymer sequestrant and method of cholesterol depletion |
Jun, 2014
(11 years ago) | |
| US5679717 | COSETTE | Method for removing bile salts from a patient with alkylated amine polymers |
Apr, 2014
(11 years ago) | |
| US7229613 | COSETTE | Method for lowering serum glucose |
Apr, 2022
(3 years ago) | |
| US6066678 | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Apr, 2014
(11 years ago) | |
| US5919832 | COSETTE | Amine polymer sequestrant and method of cholesterol depletion |
Apr, 2014
(11 years ago) | |
| US5917007 | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Apr, 2014
(11 years ago) | |
| US7101960 | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Apr, 2014
(11 years ago) | |
|
US5917007 (Pediatric) | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Oct, 2014
(11 years ago) | |
|
US5693675 (Pediatric) | COSETTE | Alkylated amine polymers |
Jun, 2015
(10 years ago) | |
|
US5679717 (Pediatric) | COSETTE | Method for removing bile salts from a patient with alkylated amine polymers |
Oct, 2014
(11 years ago) | |
|
US6066678 (Pediatric) | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Oct, 2014
(11 years ago) | |
|
US5607669 (Pediatric) | COSETTE | Amine polymer sequestrant and method of cholesterol depletion |
Dec, 2014
(11 years ago) | |
|
US5919832 (Pediatric) | COSETTE | Amine polymer sequestrant and method of cholesterol depletion |
Oct, 2014
(11 years ago) | |
|
US6433026 (Pediatric) | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Oct, 2014
(11 years ago) | |
|
US6784254 (Pediatric) | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Oct, 2014
(11 years ago) | |
|
US7101960 (Pediatric) | COSETTE | Process for removing bile salts from a patient and alkylated compositions therefor |
Oct, 2014
(11 years ago) | |
|
US7229613 (Pediatric) | COSETTE | Method for lowering serum glucose |
Oct, 2022
(3 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-608) | Oct 02, 2012 |
| Pediatric Exclusivity(PED) | Apr 02, 2013 |
| M(M-232) | Oct 20, 2024 |
Drugs and Companies using COLESEVELAM HYDROCHLORIDE ingredient
Market Authorisation Date: 26 May, 2000
Dosage: CAPSULE; FOR SUSPENSION; TABLET; BAR, CHEWABLE
How can I launch a generic of WELCHOL before it's drug patent expiration?
More Information on Dosage
WELCHOL family patents
4. Zetia patent expiration
Treatment: To reduce elevated total-c, ldl-c, apo b and non-hdl-c in patients with primary hyperlipidemia by administration of ezetimibe alone or in co...
ZETIA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5846966 (Pediatric) | ORGANON | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
Mar, 2014
(11 years ago) | |
| USRE42461 | ORGANON | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Oct, 2016
(9 years ago) | |
| USRE37721 | ORGANON | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Oct, 2016
(9 years ago) | |
|
USRE42461 (Pediatric) | ORGANON | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Apr, 2017
(8 years ago) | |
|
USRE37721 (Pediatric) | ORGANON | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Apr, 2017
(8 years ago) | |
| US7030106 | ORGANON | Sterol absorption inhibitor compositions |
Jan, 2022
(3 years ago) | |
|
US7030106 (Pediatric) | ORGANON | Sterol absorption inhibitor compositions |
Jul, 2022
(3 years ago) | |
| US5846966 | ORGANON | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
Sep, 2013
(12 years ago) | |
| US7612058 | ORGANON | Methods for inhibiting sterol absorption |
Oct, 2025
(2 months ago) | |
|
US7612058 (Pediatric) | ORGANON | Methods for inhibiting sterol absorption |
Apr, 2026
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Dec 05, 2011 |
| M(M-109) | Jan 24, 2015 |
Drugs and Companies using EZETIMIBE ingredient
Market Authorisation Date: 25 October, 2002
Dosage: TABLET
How can I launch a generic of ZETIA before it's drug patent expiration?
More Information on Dosage
ZETIA family patents